Rice body synovitis in children: a retrospective study of 6 cases and a systematic literature review of the last two decades (2006–2026) - Top-Institutions - MDSpire

Rice body synovitis in children: a retrospective study of 6 cases and a systematic literature review of the last two decades (2006–2026)

  • By

  • Qiang Ren

  • Jing Feng

  • Xuyang Cao

  • Jingyan Li

  • Tuokang Zheng

  • Yanhua Feng

  • May 13, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Children's Hospital of Hebei Province
    Children's Hospital of Hebei Province

    Shijiazhuang, Hebei

    Key Differentiators

    • Pediatrics

  • #2

    University of Cologne Children´s Hospital
    University of Cologne Children´s Hospital

    Cologne, North Rhine-Westphalia

    Key Differentiators

    • Pediatrics

  • #3

    Nationwide Children’s Hospital
    Nationwide Children’s Hospital

    Columbus, Ohio

    Key Differentiators

    • Pediatrics

  • #4

    Hacettepe University Faculty of Medicine
    Hacettepe University Faculty of Medicine

    Ankara, Ankara

    Key Differentiators

    • Pediatrics

  • #5

    Uppsala University Children’s Hospital
    Uppsala University Children’s Hospital

    Uppsala, Uppsala

    Key Differentiators

    • Pediatrics

Original Source(s)

Rice body synovitis in children: a retrospective study of 6 cases and a systematic literature review of the last two decades (2006–2026)

  • by Qiang Ren, Jing Feng, Xuyang Cao, Jingyan Li, Tuokang Zheng, Yanhua Feng

  • May 13, 2026

Related Content

Semaglutide Use Linked to Erythromelalgia Remission

Case details diagnostic workup and rapid symptom resolution following GLP-1 receptor agonist initiation.

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min